← SynDRA
ERLOTINIB
SynDRA canonical compound SYN0000783 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | EGFR |
|---|
| Mechanism of action | EGFR inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) | pancreatic cancer |
|---|
| Disease area | oncology |
|---|
All known targets
- EGFR
- SLCO2B1
- PTK2
- PLK4
- PIP4K2C
- PDGFRB
- PDGFRA
- NR1I2
- MYLK2
- MKNK2
- MKNK1
- MINK1
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
- SLCO2B1 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PTGS1
- CYP3A4
- CLK4
- ADORA3
- PKN2
- ILK
- SYK
- CHRM1
- CCKAR
- ABCB11
- OPRM1
- ABCC2
- PAK5
- PEBP1
- PIK3CB
- PIK3CA
- PIK3C2G
- PIK3C2B
- PI4KB
- PHKG2
- PHKG1
- PGR
- PFKP
- PAK3
- PDXK
- PAK6
- PDPK1
- PAK4
- PDE4D
- PDE4A
- PDE3A
- PCYT1A
- PBK
- PASK
- ABCB1
- PIM1
- PIK3CD
- PIK3CG
- PRKCB
- PRKCA
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- 5HT2A
- AHR
- VGFR2
- VGFR1
- TNI3K
- TFE3
- SO2B1
- PGFRB
- PGFRA
- NSD2
- NR1I3
- NF2L2
- MK04
- MITF
- KSYK
- KPCD2
- GCR
- ESRRA
- ESR2
- E2AK2
- CTRO
- CP3A7
- CP3A4
- CP19A
- ANDR
- VGFR3
Drug classes
- Protein Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Kinase Inhibitor
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- ERLOTINIB HYDROCHLORIDE
- TARCEVA
- Tarceva
- erlotinib hydrochloride
- tarceva
- CP-358,774-01
- OSI-774
- erlotinib HCl
- CP-358,774
- CP-358774
- CP-35877401
- R-1415
- RG-1415
- Ro-508231
- Erlotinin
- Erlotinib Base
- OSI 744
- R 1415
- Erlotinib(Tarceva)
- Tarceva (TN)
- Erlotinib, OS-774
- Erlotinib free base
- Erlotinib, Free Base
- 183321-74-6 (free base)
- NSC 718781
- CHEMBL553
- J4T82NDH7E
- CP358774
- CHEBI:114785
- MFCD02089651
- NCGC00164574-01
- CAS-183321-74-6
- NSC718781
- Erlotinib [INN:BAN]
- SR-05000001460
- UNII-J4T82NDH7E
- erlotinibum
- Erotinib
Reported adverse events
- Rash
- Hepatic failure
- Infection
- Nausea
- Stevens-Johnson syndrome
- Conjunctivitis
- Cough
- Dry skin
- Fatigue
- Headache
- Pruritus
- Pyrexia
Look up ERLOTINIB in the interactive SynDRA portal →